Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bioxytran Inc (BIXT)

Bioxytran Inc (BIXT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 5,083
  • Shares Outstanding, K 108,148
  • Annual Sales, $ 0 K
  • Annual Income, $ -2,370 K
  • EBIT $ -2 M
  • EBITDA $ -1 M
  • 60-Month Beta 2.15
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.03
  • Most Recent Earnings $0.00 on 11/14/25
  • Next Earnings Date 04/02/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0426 unch
on 01/30/26
0.0758 -43.80%
on 12/31/25
-0.0334 (-43.95%)
since 12/30/25
3-Month
0.0426 unch
on 01/30/26
0.0949 -55.11%
on 12/26/25
-0.0274 (-39.14%)
since 10/30/25
52-Week
0.0391 +8.95%
on 10/24/25
0.2283 -81.34%
on 04/09/25
-0.0574 (-57.40%)
since 01/30/25

Most Recent Stories

More News
Bioxytran Provides Corporate Update Highlighting Momentum Across Its Multi-Platform Pipeline

Bioxytran Provides Corporate Update Highlighting Momentum Across Its Multi-Platform Pipeline

BIXT : 0.0426 (-9.36%)
Bioxytran Announces Initiation of Coverage of its Stock by Independent Research

BOSTON, MASSACHUSETTS, Nov. 13, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical-stage biotech company focused on innovative treatments for stroke, Alzheimer’s,...

BIXT : 0.0426 (-9.36%)
Bioxytran Completes Randomized Clinical Trial For its Broad-Spectrum Antiviral Drug

Data from the dose optimization trial expected soon ProLectin-M is positioned as the first oral antiviral sugar chemistry drug BOSTON, MASSACHUSETTS, Oct. 29, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN,...

BIXT : 0.0426 (-9.36%)
Bioxytran Unveils Revolutionary Precision Diagnostics on Tissue Oxygenation

Game changer for stroke, Alzheimer’s, and beyond  Shifting from peripheral to tissue-specific oxygenation monitoring BOSTON, MASSACHUSETTS, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC....

BIXT : 0.0426 (-9.36%)
Bioxytran’s Breakthrough Broad-Spectrum Antiviral Technology Poised to Revolutionize Respiratory Infection Treatment

- ProLectin-M is currently being developed under an active Investigational New Drug (IND) application with the FDA BOSTON, MASSACHUSETTS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:...

BIXT : 0.0426 (-9.36%)
Bioxytran Secures a Source of GMP Quality Camel Hemoglobin

BIXT : 0.0426 (-9.36%)
Bioxytran’s Groundbreaking Stroke & Alzheimer’s Tech Gains Validation That Measures Oxygenation Uptake During Strokes

BIXT : 0.0426 (-9.36%)
Bioxytran’s Antiviral Breakthrough Featured in University of Georgia’s $100M HPAI Poultry Innovation Grand Challenge Submission

BIXT : 0.0426 (-9.36%)
Bioxytran Completes Dose Optimization of Antiviral, ProLectin-M

BIXT : 0.0426 (-9.36%)
Bioxytran Marks 50 years of Mitochondrial Research with BXT-25 Advancements

BIXT : 0.0426 (-9.36%)

Business Summary

BioXyTran Inc. is a biotechnology company. It develops anti-necrosis drugs to treat medical conditions resulting from ischemia. The company's product pipeline consists of BXT-25 and BXT-252 which are in clinical stage. BioXyTran Inc. is based in Newton, United States.

See More

Key Turning Points

3rd Resistance Point 0.0524
2nd Resistance Point 0.0505
1st Resistance Point 0.0465
Last Price 0.0426
1st Support Level 0.0406
2nd Support Level 0.0387
3rd Support Level 0.0347

See More

52-Week High 0.2283
Fibonacci 61.8% 0.1560
Fibonacci 50% 0.1337
Fibonacci 38.2% 0.1114
Last Price 0.0426
52-Week Low 0.0391

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar